Plain language summary of the HIMALAYA study: tremelimumab and durvalumab for unresectable hepatocellular carcinoma (liver cancer).
Future oncology (London, England)(2023)
Abstract
Overall, STRIDE is more effective than sorafenib for people with unresectable HCC. NCT03298451 (HIMALAYA) (ClinicalTrials.gov).
MoreTranslated text
Key words
clinical trial, durvalumab, hepatocellular carcinoma, immunotherapy, lay summary, liver cancer, plain language summary, Sorafenib, tremelimumab
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined